ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2017, Vol. 9 ›› Issue (1): 44-46.doi: 10.3969/j.issn.1674-3865.2017.01.013

• 临床研究 • 上一篇    下一篇

双歧杆菌三联活菌肠溶胶囊联合思密达治疗婴幼儿腹泻的疗效观察

刘卫萍，廖超平，陈艳丽   

  1. 518110 广东 深圳，深圳市龙华区中心医院岗头社区健康服务中心
  • 出版日期:2017-02-25 发布日期:2017-12-18
  • 通讯作者: 刘卫萍，E-mail:szlwp_120@sina.com
  • 作者简介:刘卫萍(1974-)，女，主治医师。研究方向：小儿内科疾病的诊治

Observation of clinical effect of Bifid Triple Viable Capsules Dissolving at Intestines combined with smecta in treatment of infantile diarrhea

LIU Weiping, LIAO Chaoping, CHEN Yanli   

  1. Gangtou Community Health Service Center of Central Hospital of Longhua District of Shenzhen City, Shenzhen 518110,China
  • Online:2017-02-25 Published:2017-12-18

PDF (PC)

347

摘要：
目的: 观察双歧杆菌三联活菌肠溶胶囊联合思密达治疗婴幼儿腹泻的效果。
方法: 2014年9月至2016年1月深圳市龙华区中心医院岗头社区健康服务中心门诊收治腹泻患儿98例，随机分为观察组和对照组各49例。对照组实施常规疗法，观察组在对照组治疗基础上应用双歧杆菌三联活菌肠溶胶囊联合思密达治疗，疗程1周，观察两组患儿治疗效果、症状体征恢复时间及不良反应。
结果: 观察组治疗总有效率为91.8%(45/49)，高于对照组75.5%(37/49)，差异有统计学意义(P<0.05)。观察组患儿体温、大便次数、大便性状恢复正常时间均较观察组短，差异有统计学意义(P<0.05)。两组患儿均未发生严重不良反应。
结论: 双歧杆菌三联活菌肠溶胶囊联合思密达治疗婴幼儿腹泻疗效显著，可快速控制病情，减轻患儿痛苦，且安全性高，可作为小儿腹泻首选用药方案。

关键词: 腹泻, 双歧杆菌三联活菌肠溶胶囊, 思密达, 疗效, 儿童

Abstract:
Objective: To observe the effect of Bifid Triple Viable Capsules Dissolving at Intestines combined with smecta in treatment of infantile diarrhea.
Methods: Totally 98 cases of children with diarrhea who accepted treatments in Gangtou Community Health Service Center of Central Hospital of Longhua District of Shenzhen City from September 2014 to January 2016 were randomly divided into observation group and control group, with 49 cases in each group. The control group received routine therapy, while the observation group, on the basis of the treatment for the control group, were treated with the Bifid Triple Viable Capsules Dissolving at Intestines combined with smecta. Then, after 1 week of treatment, the treatment effect, recovery time and adverse reaction of two groups of patients were observed.
Results: The total effective rate in the observation group was 91.8%(45/49), which was higher than the control group(75.5%, 37/49), and the difference was statistically significant(P<0.05). The recovery time of body temperature, stool frequency and stool character in the observation group was shorter than that in the control group, the difference being statistically significant(P<0.05). There was no serious adverse reaction in the two groups.
Conclusion: The clinical effects of Bifid Triple Viable Capsules Dissolving at Intestines combined with smecta in treatment of infantile diarrhea are significant, which can quickly control the disease, reduce the pain of children, and the safety is high, thus it can be used as the preferred drug treatment for children with diarrhea.

Key words: Diarrhea, Bifid Triple Viable Capsules Dissolving at Intestines, Smecta, Clinical effect, Children